ArticleFrontiers in oncology2023
Safety and feasibility of robotic-assisted thoracic surgery after neoadjuvant chemoimmunotherapy in non-small cell lung cancer.
Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Robotic-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer after neoadjuvant immunotherapy: a systematic review and meta-analysis.Journal of robotic surgery · 2026Pooled it
- Minimally invasive surgery vs. open thoracotomy for non-small-cell lung cancer with N2 disease: a systematic review and meta-analysis.Frontiers in medicine · 2023Pooled it
- Considerations regarding a meta-analysis investigating the efficacy and safety of robotic-assisted thoracic surgery after neoadjuvant therapy in non-small cell lung cancer.Updates in surgery · 2026Article
- Article
- Clinical efficacy and safety of robotic-assisted thoracic surgery after neoadjuvant therapy in non-small cell lung cancer: a systematic review and meta-analysis.Updates in surgery · 2026Article
- Nationwide Implementation of Neoadjuvant Nivolumab-Based Chemo-Immunotherapy for Resectable NSCLC: Surgical Outcomes from a Prospective Multicenter Study.Annals of surgical oncology · 2026Article
- Robotic Thoracic Surgery After Neoadjuvant Chemo-Immunotherapy for NSCLC: A Narrative Review.Cancers · 2026Review
- Current state of evidence for RATS lobectomy for NSCLC.Journal of cardiothoracic surgery · 2026Review
- Multicenter study comparing outcomes of robotic versus video-assisted thoracoscopic resection of non-small cell lung cancer following neoadjuvant chemoimmunotherapy.Journal of robotic surgery · 2026Article
- The evolving role of neoadjuvant immunotherapy in resectable non-small cell lung cancer: a narrative review.Journal of thoracic disease · 2026Review
- Outcomes of robotic anatomic lung resection after neoadjuvant therapy for non-small cell lung cancer.Frontiers in surgery · 2026Article
- Robotic-Assisted Thoracoscopic Surgery Versus Video-Assisted Thoracoscopic Surgery: Which Is the Preferred Approach for Early-Stage NSCLC?Journal of clinical medicine · 2025Review
- Review
- Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising Outcomes.Cancers · 2024Article
- Short-term outcomes of robot-assisted versus video-assisted thoracoscopic surgery for non-small cell lung cancer patients with neoadjuvant immunochemotherapy: a single-center retrospective study.Frontiers in immunology · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate the safety and feasibility of robotic-assisted thoracic surgery (RATS) after neoadjuvant chemoimmunotherapy in NSCLC. Methods: We retrospectively collected data for NSCLC patients who received thoracic surgery after neoadjuvant chemoimmunotherapy from May 2020 to August 2022. Surgery details, pathological response, and perioperative outcome were compared between video-assisted thoracic surgery (VATS) group and RATS group. Inverse probability of treatment weighting (IPTW) was used to equal the baseline characteristics. Results: A total of 220 patients were divided into 78 VATS patients and 142 RATS patients. There was no 90-day mortality in either group. RATS patients demonstrated better results in conversion rate to thoracotomy (VATS vs. RATS: 28.2% vs. 7.5%, Conclusions: RATS reduced the risk of conversion to thoracotomy, provided a better yp-N stage evaluation, and improved pain score; this suggests that RATS is safe and feasible for NSCLC patients after neoadjuvant chemoimmunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.